Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of RNA-based Mpox Vaccine Candidate BNT166a
NCT05988203Phase 2Completed
- Sponsor
- BioNTech SE
- Start
- Sep 2023
- Primary completion
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of BNT166 in mpox, sponsored by BioNTech SE. Started Sep 2023; status: completed.
02
Drugs
BNT166
03
Conditions
mpox
Beyond the preview
Go deeper on NCT05988203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05988203.